|
Market Closed -
London S.E.
19:35:14 11/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,531.00 GBX | +2.20% |
|
-3.89% | -1.23% |
| 09-09 | Hikma Pharmaceuticals Submits Epinephrine Nasal Spray for Regulatory Review in US, Europe, UK, and Canada | CI |
| 09-08 | Barclays Upgrades Hikma Pharmaceuticals to Equalweight, Boosts PT | MT |
| Market Cap | 4.36B 3.75B 3.55B 3.22B 6.04B 416B 6.07B 42.2B 16.23B 212B 16.36B 16B 669B | P/E 2026 * |
11.3x | P/E 2027 * | 10x |
|---|---|---|---|---|---|
| Enterprise Value | 5.84B 5.03B 4.76B 4.32B 8.1B 558B 8.14B 56.59B 21.76B 284B 21.93B 21.45B 897B | EV / Sales 2026 * |
1.69x | EV / Sales 2027 * | 1.57x |
| Free-Float |
63.16% | Yield 2026 * |
4.17% | Yield 2027 * | 4.42% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| HIK | Delayed | |
CBOE
| HIK | Real-time | |
|
Tradegate
| H5P | Real-time | |
|
OTC Markets
| HKMPF | Delayed | |
|
Deutsche Boerse AG
| H5P | Delayed | |
|
Börse Stuttgart
| H5P | Delayed | |
|
Boerse Muenchen
| H5P | Real-time |
Last Transcript : Hikma Pharmaceuticals PLC
| 1 day | +2.20% | ||
| 1 week | -3.89% | ||
| Current month | -5.26% | ||
| 1 month | -7.04% | ||
| 3 months | +3.45% | ||
| 6 months | +26.63% | ||
| Current year | -1.23% |
| 1 week | 1,483.69 |  | 1,638 |
| 1 month | 1,483.69 | | 1,673 |
| Current year | 1,187 | | 1,762 |
| 1 year | 1,187 | | 1,865 |
| 3 years | 1,187 | | 2,360 |
| 5 years | 1,174.5 | | 2,507 |
| 10 years | 814.2 | | 2,768 |
| Manager | Title | Age | Since |
|---|---|---|---|
Said Darwazah
CEO | Chief Executive Officer | 69 | 01/12/2025 |
Areb Kurdi
DFI | Director of Finance/CFO | - | 26/02/2026 |
| Chief Tech/Sci/R&D Officer | 64 | 26/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 14/10/2005 | |
Khalid Nabilsi
BRD | Director/Board Member | 54 | 15/12/2025 |
Said Darwazah
CHM | Chairman | 69 | 15/05/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/06/26 | Sell | Investor Relations Manager | -26,558 | 0.0124% | ||
| 01/06/26 | Exercice | Director | 72,763 | 0.0339% | ||
| 01/06/26 | Exercice | Director | 20,650 | 0.0096% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.20% | -3.89% | -6.19% | -26.75% | 4.36B | |
| -0.65% | -2.93% | +47.70% | +86.17% | 994B | |
| -0.29% | -3.51% | +49.15% | +62.35% | 640B | |
| +0.83% | +0.26% | +17.76% | +72.25% | 454B | |
| -0.38% | -3.59% | +30.13% | +35.17% | 337B | |
| -0.09% | -13.54% | +13.34% | +24.95% | 261B | |
| -0.43% | -2.48% | -0.73% | +9.58% | 246B | |
| -1.34% | -13.70% | +36.53% | +44.96% | 204B | |
| -3.44% | -7.51% | -20.63% | -59.44% | 190B | |
| -0.75% | -4.82% | +25.46% | +87.14% | 178B | |
| Average | -0.43% | -5.57% | +19.25% | +33.64% | 350.91B | |
| Weighted average by Cap. | -0.50% | -4.41% | +30.91% | +54.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.46B 2.98B 2.82B 2.56B 4.8B 331B 4.82B 33.52B 12.89B 168B 12.99B 12.71B 531B | 3.6B 3.1B 2.94B 2.66B 5B 344B 5.02B 34.9B 13.42B 175B 13.53B 13.23B 553B |
| Net income | 412M 355M 336M 305M 572M 39.38B 575M 3.99B 1.54B 20.04B 1.55B 1.51B 63.31B | 453M 391M 370M 335M 629M 43.32B 632M 4.39B 1.69B 22.04B 1.7B 1.67B 69.64B |
| Net Debt | 1.48B 1.28B 1.21B 1.1B 2.06B 142B 2.07B 14.38B 5.53B 72.15B 5.58B 5.45B 228B | 1.31B 1.13B 1.07B 969M 1.82B 125B 1.83B 12.7B 4.88B 63.69B 4.92B 4.81B 201B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | GBX 1,531.00 | +2.20% | 382,779 |
| 10/09/26 | GBX 1,498.00 | -2.41% | 639,527 |
| 09/09/26 | GBX 1,535.00 | -3.82% | 571,231 |
| 08/09/26 | GBX 1,596.00 | -0.25% | 504,097 |
| 07/09/26 | GBX 1,600.00 | +0.44% | 375,580 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HIK Stock
Select your edition
All financial news and data tailored to specific country editions
